BioVenture VoiCes with Chris Garabedian

Episode 42: Nextech's Thilo Schroeder

Having been an early investor in many recent successes such as Revolution Medicines, Peloton, and Parabilis Medicines, he describes his investment philosophy and focus on precision oncology companies. Plus, his early life, getting hands on experience in biotech at Micromet, and learning from some of the top investors and scientific advisors in the industry.

Episode 41: Forbion's Nanna Lüneborg

Nanna Luneborg discusses hear career and joining Forbion. She describes the firm's investment approach, and her experience with everything from seed, to private, and to public investing in life sciences. Plus, thoughts on China and AI in biotech.

Episode 40: GV's Krishna Yeshwant

He describes his well-rounded background of studying and working in both software in Silicon Valley and Medicine in Boston, and the start of GV. He describes a conservative start to investing at GV, but also today how Alphabet's scale and cash gives them the ability to ride cycles and make concentrated bets on companies the team has conviction on.

Episode 39: SV Health Investors' Kate Bingham

Kate Bingham describes her early life and a serendipitous opportunity to work at Vertex in the early 1990's. She then discusses joining SV Health and describes its investment approaches, the Dementia Discovery Fund, being on the UK's Vaccine Taskforce during Covid, and more.

Episode 38: Deerfield Management's Jason Fuller

He discusses his education and joining the Langer Lab at MIT, early experiences in venture, including at Third Rock and NEA, and gaining operational experience at Jounce before joining Deerfield. Plus, areas that interest him today and how he thinks about AI.